Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly signage during a groundbreaking ceremony for Eli Lilly and Company's pharmaceutical manufacturing campus at Generation Park in Houston, Texas, US, on Monday, Sept. 21, 2026. Mark Felix | Bloomberg | Getty ImagesEli Lilly on Wednesday said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 diabetes. The combo therapy met the study's main goals in a population that typically struggles to lose weight. The results boost hopes that it could serve as an alternative blockbuster treatment option for people who didn't respond to or see the results they wanted on the current GLP-1 products on the market. Lilly said it plans to start Phase 3 trials on the regimen at the end of the year. The combination treatment combines Lilly's experimental drug eloralintide, which targets amylin – a hormone in the pancreas involved in appetite and satiety – with a low dose of tirzepatide, the active ingredient in its obesity injection Zepbound and its diabetes counterpart Mounjaro. Tirzepatide targets two gut hormones, GLP-1 and GIP. Lilly believes that hitting all three p...